ROLE OF VITAMIN D SUPPLEMENTATION IN THE PREVENTION OF INFECTION AND SEVERE COURSE IN COVID-19: TESTING THE HYPOTHESIS

Received: June 21, 2021
Accepted: August 30, 2021

Mohit Goyal1* https://orcid.org/0000-0002-7228-2890
Neha Goyal2
1Division of Rheumatology and Clinical Immunology, CARE Pain & Arthritis Centre, Goyal Hospital, Udaipur, India
2Division of Interventional Pain Management, CARE Pain & Arthritis Centre, Goyal Hospital, Udaipur, India

*Corresponding author: Mohit Goyal, MD, FACP, Consultant, Division of Rheumatology and Clinical Immunology, CARE Pain & Arthritis Centre, Goyal Hospital, Udaipur 313002, India;
Twitter handle: @drmohitgoyal; E-mail: dr.mohitgoyal@gmail.com

Abstract
The coronavirus disease 2019 (COVID-19) pandemic has disrupted the normal activities of various settings, including clinics, laboratories, and libraries. As the world deals with the fast-mutating causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), apart from the search for the best vaccine candidate, efforts towards repurposing existing molecules to save lives must continue. Considerable interest has centered around the implications of vitamin D deficiency and its supplementation on the outcomes in patients with COVID-19. We hypothesize that vitamin D supplementation has the potential to confer protection against SARS-CoV-2 infection and a severe COVID-19 course.

Various animal, human observational as well as intervention studies have shown a protective role of vitamin D in COVID-19. More robustly designed studies where vitamin D is supplemented prophylactically and administered to those already infected are needed to determine the precise contribution of this supplementation in preventing SARS-CoV-2 infection and modifying the course of COVID-19.

Keywords: Coronavirus disease 2019, Severe acute respiratory syndrome coronavirus 2, Pandemic, Cholecalciferol, Calcitriol, Clinical trial, Vitamin D, Hypothesis

How to cite: Goyal M, Goyal N. Role of vitamin D supplementation in the prevention of infection and severe course in COVID-19: testing the hypothesis. Cent Asian J Med Hypotheses Ethics 2021:2(3):146-152. https://doi.org/10.47316/cajmhe.2021.2.3.03

INTRODUCTION
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutates, we now know of variants that are more transmissible than their predecessors [1,2]. Most vaccines have shown impressive efficacy in various phases of the trials, but their efficacy against the mutant strains remains to be established [2–4]. While efforts towards vaccination must continue, an eye should remain on repurposing existing drugs towards minimizing the damage caused by coronavirus disease 2019 (COVID-19).

There have historically been studies that have implicated vitamin D deficiency (VDD) as a factor influencing the development or worsening of infections, inflammation and allergies. Studies have identified VDD as a risk factor for community-acquired pneumonia and it has also
been associated with worse outcomes, including higher mortality in respiratory infections and sepsis [5,6]. Researchers have observed that patients with tuberculosis have significantly lower vitamin D levels, and higher levels reduced time to sputum and culture conversions, thus vitamin D supplementation should be considered along with anti-tubercular therapy [7–9]. Evidence has emerged that vitamin D supplementation potentially mitigates SARS-CoV-2 infection and reduces the severity of COVID-19. Observational data have indicated a protective role for vitamin D with regard to SARS-CoV-2 infection and COVID-19 [10,11]. The pandemic restrictions and stay-at-home orders have increased the prevalence of VDD [12]. Furthermore, observational data suggest a higher rate of infections and poorer prognosis in those with VDD [13].

**HYPOTHESIS**

Our understanding of this vitamin, in-vitro models, and recent research suggest that vitamin D supplementation may have roles from preventing SARS-CoV-2 infection to reducing COVID-19 severity, as well as in mitigating the inflammation induced in the later phase of the disease. We hypothesize that vitamin D supplementation has the potential to confer protection against SARS-CoV-2 infection and severe COVID-19.

**HYPOTHESIS TESTING**

Experimental models have revealed that 1,25-dihydroxycalciferol (calcitriol), the active form of vitamin D, downregulates the expression of angiotensin-converting enzyme 2 [14]. Therefore, it can reduce the entry of SARS-CoV-2 into the cells and is thus likely to be of enhanced benefit in those with diabetes. This means that vitamin D is likely to have a role before a person contracts SARS-CoV-2 infection, and also after one contracts the infection and before they develop COVID-19. Cathelicidin antimicrobial peptide (CAMP) has an antioxidant activity, besides its role in destroying microbial membranes. It has been shown to reduce the severity of lung injury. In infections, vitamin D is converted to the active form in the alveolar epithelial cells, which then upregulates the production of CAMP [15]. It also reduces vascular permeability and cell apoptosis [16]. Calcitriol downregulates Th1 cells, tumor necrosis factor-alpha, nuclear factor-κB, and interferon-gamma [17–20]. It also reduces the production of interleukins, thus it has a potential role in dampening the cytokine release syndrome [21]. The various possible mechanisms through which vitamin D can provide protection in COVID-19 are shown in figure 1.

Ecological studies found a higher incidence of SARS-CoV-2 positivity in countries with a lower national average 25-hydroxyvitamin D (25-OHD) levels [10]. Researchers also attempted to find the relation between the latitudinal position of countries and the number of SARS-COV-2 cases [22]. A Swiss study published as early as May 2020 revealed that subjects who had tested positive for SARS-CoV-2 had comparatively lower 25-OHD levels [13]. A few months later, a larger study from the US found that SARS-CoV-2 positivity was inversely related to circulating 25-OHD levels [11]. A study of over 80,000 subjects in the North West of England who had a documented 25-OHD level in the preceding 12 months found that VDD was associated with an increased risk of hospitalization [23]. The initial human studies were mostly retrospective, which by their very nature have certain limitations [24].

In late 2020, a randomized, placebo-controlled study was conducted on SARS-CoV-2 positive, asymptomatic or mildly symptomatic individuals in India. The authors found that a significantly higher percentage of those who received 60,000 IU of cholecalciferol daily for 7 days (versus those who received placebo) tested negative on day 14 and also had lower fibrinogen levels [25]. A pilot randomized trial in Spain on patients hospitalized with COVID-19 compared those who received the best available treatment with those who additionally received calcifediol on days 0, 3, and 7, and then weekly. Two percent (n = 1) in the calcifediol group versus 50% (n = 13) required transfer to the intensive care unit (ICU) [26]. A recently published study on 103 COVID-19 in-patients in North Italy found that the severely ill had a mean 25-OHD level of 18.2 ± 11.4 ng/mL versus 30.3 ± 8.5 ng/mL in those who remained mildly symptomatic. The levels correlated inversely with interleukin-6 levels, need for transfer to the ICU, and mortality [27]. Multivariate analysis of an Israeli cohort found that 25-OHD levels were independent risk factors for COVID-19 and hospitalization [28]. A quasi-experimental study on the frail elderly in France found that bolus doses of vitamin D given regularly resulted in less severe disease and improved survival [29]. At the same time, there have been some studies, including a randomized trial that failed to show benefit with vitamin D supplementation in COVID-19 [30].

Ongoing trials and studies in the coming days are likely to shed more light on the role of vitamin D in the context of COVID-19. COVIDENCE UK is a large prospective study that plans to recruit over 12,000 subjects. Those who join the study will fill a vitamin D status and other risks assessment questionnaire, and will then be followed up to document the development of SARS-CoV-
2 infection and COVID-19 [31]. There are ongoing trials on asymptomatic, mildly symptomatic, and non-hospitalized patients who have tested positive for SARS-CoV-2. While one such trial is studying the role of a single bolus dose in reducing the time taken to test negative after a positive test, another trial is testing the efficacy of smaller doses given daily for 28 days in reducing hospitalisations and mortality [32,33]. Ongoing clinical trials are also looking at the role of vitamin D supplementation in reducing the risk of SARS-CoV-2 infection in healthcare workers [34,35]. Then there are ongoing studies on hospitalized patients who have developed pneumonia, and researchers are studying the role of vitamin D supplementation in reducing mortality [36]. In France, CoVitTrial, designed to compare a single dose of 400,000 IU vitamin D with a single dose of 50,000 IU vitamin D in patients with high-risk features has finished recruiting [37]. A study (CORONAVIT) on a large cohort in the UK aims to compare the effect of high dose versus low dose supplementation of vitamin D on the risk of SARS-CoV-2 infection as well as severe COVID-19 [38].

Community-based, as well as hospital-based studies, are needed to precisely delineate the place and impact of vitamin D supplementation on SARS-CoV-2 infection and COVID-19. Studies for determining the prevalence of vitamin D deficiency, estimation of serum levels, and meticulous registries of SARS-CoV-2 infections will help determine the precise nature of the association of vitamin D levels and risk of infection. A negative correlation would implicate a role of vitamin D supplementation in SARS-CoV-2 prophylaxis. Case-control studies comparing COVID-19 hospitalized patients with and without VDD will help determine its influence on the course of the disease. Similarly, randomized trials recruiting patients admitted with COVID-19 will help determine the impact of vitamin D supplementation on outcomes in COVID-19.

The role of VDD in COVID-19 is of particular interest to the countries of the region as studies have shown that VDD is far more prevalent in Central Asia [39,40]. Researchers have also noted a dearth of studies on the subject from this region, highlighting the relative lack of concern and awareness [41].

ETHICAL CONSIDERATIONS
There has been a lack of awareness and due attention to vitamin D levels, and their correction has not been accorded. The role of vitamin D in health outside of the musculoskeletal system remains a not-so-widely known subject. While the stay-at-home orders are being enforced to limit the spread of infection, they lead to a decline in the serum levels of 25-OHD, and necessary awareness needs to be raised and steps taken to prevent VDD. Further studies may also provide the rationale for checking the serum levels of 25-OHD in those admitted for COVID-19, and for making corrections.

CONCLUSION
While the jury is still out on the role of vitamin D supplementation in preventing SARS-CoV-2 infection and a severe COVID-19 course, it might be pragmatic to supplement this vitamin as per the national guidelines. At such doses, there does not appear to be a significant risk of adverse effects or toxicity and are outweighed by the potential benefits.

FUNDING
None

AUTHOR CONTRIBUTIONS
MG generated the hypothesis and drafted and revised the manuscript. NG performed the literature search, revised the manuscript. MG and NG approved the final manuscript and take full responsibility for the integrity of all aspects of the work.

CONFLICTS OF INTEREST
Both authors have completed the ICMJE Disclosure Form (http://www.icmje.org/disclosure-of-interest/; available on request). The authors declare that there are no potential conflicts of interest.
Figure 1. Possible mechanisms for the protective role of vitamin D in coronavirus disease 2019 (ACE2, angiotensin-converting enzyme 2; CAMP, Cathelicidin antimicrobial peptide)

REFERENCES

1. Alizon S, Haim-Boukobza S, Fouloungne V, Verdurme L, Trombert-Paolantoni S, Lecorche E, et al. Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021. Eurosurveillance 2021;26(28):2100573.
2. Farinholt T, Doddapaneni H, Qin X, Monen V, Meng Q, Metcalf G, et al. Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections. MedRxiv 2021(12):21258780.
3. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021;397(10293):2461–2462.
4. Yadav PD, Sapkal GN, Ella R, Sahay RR, Nyayanit DA, Patil DY, et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med 2021;taab104.
5. Zhou Y-F, Luo B-A, Qin L-L. The association between vitamin D deficiency and community-acquired pneumonia: A meta-analysis of observational studies. Medicine (Baltimore). 2019;98(38):e17252.
6. Cariolou M, Cupp MA, Evangelou E, Tzoulaki I, Berlanga-Taylor AJ. Importance of vitamin D in acute and critically ill children with subgroup analyses of sepsis and respiratory tract infections: a systematic review and meta-analysis. BMJ Open 2019;9(5):e027666.
7. Huang S-J, Wang X-H, Liu Z-D, Cao W-L, Han Y, Ma A-G, et al. Vitamin D deficiency and the risk of tuberculosis: a meta-analysis. Drug Des Devel Ther 2017;11:91–102.
8. Zhang J, Chen C, Yang J. Effectiveness of vitamin D supplementation on the outcome of pulmonary tuberculosis treatment in adults: a meta-analysis of randomized controlled trials. Chin Med J (Engl) 2019;132(24):2950–2959.
9. Wu H-X, Xiong X-F, Zhu M, Wei J, Zhuo K-Q, Cheng D-Y. Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: a systematic review and meta-analysis. BMC Pulm Med 2018;18(1):108.
10. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res 2020;32(7):1195–1198.
11. Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS One. 2020;15(9):e0239252.
12. Rustecka A, Maret J, Drab A, Leszczyńska M, Tomaszewska A, Lipińska-Opalka A, et al. The impact of COVID-19 pandemic during 2020-2021 on the vitamin D serum levels in the paediatric population in Warsaw, Poland. Nutrients 2021;13(6):1990.

13. D’Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, et al. 25-Hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients 2020;12(5):1359.

14. Ali RM, Al-Shorbagy MY, Helmy MW, El-Abhar HS. Role of Wnt/β-catenin, Ang II/TGFβ, ACE2, NF-κB, and IL-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone. Eur J Pharmacol 2018;831:68–76.

15. Jiang J-S, Chou H-C, Chen C-M. Cathelicidin attenuates hyperoxia-induced lung injury by inhibiting oxidative stress in newborn rats. Free Radic Res and Medical Science 2020;150:23–29.

16. Kong J, Zhu X, Shi Y, Liu T, Chen Y, Bhan I, et al. VDR attenuates acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system. Mol Endocrinol 2013;27(12):2116–2125.

17. Ardizzone S, Cassinotti A, Trabattoni D, Manzionna G, Rainone V, Bevilacqua M, et al. Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int J Immunopathol Pharmacol 2009;22(1):63–71.

18. Peterson CA, Hefferman ME. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm (Lond) 2008;5:10.

19. Talmor Y, Bernheim J, Klein O, Green J, Rashid G. Calciotril blunts pro-atherosclerotic parameters through NFκappaB and p38 in vitro. Eur J Clin Invest. 2008;38(8):548–554.

20. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221(4616):1181–1183.

21. Palmer MT, Lee YK, Maynard CL, Oliver JR, Bikle DD, Jetten AM, et al. Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J Biol Chem 2011;286(2):997–1004.

22. Walrand S. Autumn COVID-19 surge dates in Europe correlated to latitudes, not to temperature-humidity, pointing to vitamin D as contributing factor. Sci Rep 2021;11(1):1981.

23. Jude EB, Ling SF, Allcock R, Yeap BXY, Pappachan JM. Vitamin D deficiency is associated with higher hospitalisation risk from COVID-19: a retrospective case-control study. J Clin Endocrinol Metab 2021;dgab439.

24. Talari K, Goyal M. Retrospective studies - utility and caveats. J R Coll Physicians Edinb 2020;50(4):398–402.

25. Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). Postgrad Med J 2020;postgradmed-2020-139065.

26. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. “Effect of calcifiediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”. J Steroid Biochem Mol Biol 2020;203:105751.

27. Campi I, Gennari L, Merlotti D, Mingiano C, Frosali A, Giovanelli L, et al. Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. BMC Infect Dis 2021;21(1):566.

28. Merzon E, Tworowski D, Gorohovsky A, Vinker S, Golan Cohen A, Green I, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J 2020;287(17):3693–3702.

29. Annweiler G, Corvaisier M, Gautier J, Dubée V, Legrand E, Sacco G, et al. Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: The GERIA-COVID Quasi-Experimental Study. Nutrients 2020;12(11):E3737.

30. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial. JAMA 2021;325(11):1053–1060.

31. COVIDENCE UK - COVIDENCE UK. Available from: https://www.qmul.ac.uk/covidence/ [Accessed June 21, 2021].

32. Belguithasma S. The effect of vitamin D supplementation on recovery delays for non severe COVID-19 cases. Available from: https://clinicaltrials.gov/ct2/show/NCT04883203 [Accessed June 17, 2021]

33. MD JEM. A cluster-randomized, double-blind, placebo-controlled study to evaluate the efficacy of vitamin D3 supplementation to reduce disease severity in persons with newly diagnosed COVID-19 infection and to prevent infection in household members. Available from: https://clinicaltrials.gov/ct2/show/NCT04536298 [Accessed June 17, 2021]
34. Ducharme PF. PROTECT RCT (PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams. Available from: https://clinicaltrials.gov/ct2/show/NCT04483635 [Accessed June 17, 2021]

35. Keever MAV. Efficacy of vitamin D supplementation to prevent the risk of acquiring or evolving into the severe form of COVID-19 in healthcare workers caring for patients with the disease. Blinded Randomized Clinical Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT04535791 [Accessed June 17, 2021]

36. Bioaraba Health Research Institute. Efficacy of treatment with vitamin D in patients diagnosed with COVID-19 who presenting vitamin D deficiency and pneumonia. Available from: https://clinicaltrials.gov/ct2/show/NCT04621058 [Accessed June 17, 2021]

37. Annweiler C, Beaudenon M, Gautier J, Simon R, Dubée V, Gonsard J, et al. COVID-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial. Trials 2020;21(1):1031.

38. Queen Mary University of London. Phase 3 randomised controlled trial of vitamin D supplementation to reduce risk and severity of COVID-19 and other acute respiratory infections in the UK Population. Available from: https://clinicaltrials.gov/ct2/show/NCT04579640 [Accessed June 17, 2021]

39. Ganmaa D, Holick MF, Rich-Edwards JW, Frazier LA, Davaalkham D, Ninjin B, et al. Vitamin D deficiency in reproductive age Mongolian women: a cross sectional study. J Steroid Biochem Mol Biol 2014;139:1–6.

40. Güngör D, BiÇer I, Pereira RR, Rasulov AS, Rachimov AU, Mavlyanov S, et al. Prevalence of vitamin D deficiency in Samarkand, Uzbekistan. Journal of Nutritional & Environmental Medicine. 2008;17(4):223–231.

41. Grant WB. Comparing vitamin D status in Central Asia and northern Europe. Cent Asian J Med Hypotheses Ethics. 2020;1(1):33–42.
COVID-19 КЕЗІНДЕ ЖУҚПАНЫҢ ТАРАЛУЫН ЖӘНЕ АУРУДЫҢ АУЫР АҒЫМЫН БОЛДЫРМАУДА Д ДӘРУМЕНІҢІҢ РОЛІ: ГИПОТЕЗАНЫ ТЕКСЕРУ

Тұйіндеме
2019 жылығы коронавирустарық ауру пандемиясы (COVID-19) клиникаларда, зертханада және кітапханада медициналық қауымдастықты қамтыды. Әлем тез мутацияга ұшырайтын бұл вируспен құрылығы жатқандықтан, вакцинаның ең жақсы кандидатын табуу қатар, адам өмірін құтқару үшін қоңырқа қалып тасықтарға мүмкіндік етті. Медициналық гипотеза, этикалық және білім беру құрылысындағы қабылдау үшін әртіс менін дәріміз ушын бұл дәріміз бөлініп, коронавирус 2, пандемия, холекальциферол, кальцитриол, клинические испытания, білім беру және және коронавирустарың өзгертілуінің қысқырғығы.</p>

Құжат, әдет, мәдениет және етік өрнектер арқылы ушық және жайықтарды жақынтуу үшін. Бұл дәріміз көп қолданысқа ұшып қалып тасықтарға мүмкіндік етті. Медициналық гипотеза, этикалық және білім беру құрылысындағы қабылдау үшін әртіс менін дәріміз бөлініп, коронавирус 2, пандемия, холекальциферол, кальцитриол, клинические испытания, білім беру және және коронавирустарың өзгертілуінің қысқырғығы.

Тұйінді сөздет: 2019 коронавирус ауруы, ауыр қарсы ұқсатылатын синдром, коронавирус 2, пандемия, холекальциферол, кальцитриол, клиникалық сынақтар.

Дайыкың үшін: Гоял М., Гоял Н. COVID-19 кезінде жұқпанның таралуын және аурудың ауыр ағымын болдырмада D дәрүменіңің рөлі: гипотезаны тексеру. Медициналық гипотеза мен этикалық болып, Орта Азиялық журналы. 2021:2(3):146-152. https://doi.org/10.47316/cajmhe.2021.2.3.03

РОЛЬ ВИТАМИНА D В ПРОФИЛАКТИКЕ РАСПРОСТРАНЕНИЯ ИНФЕКЦИИ И ТЯЖЕЛОГО ТЕЧЕНИЯ ЗАБОЛЕВАНИЯ ПРИ COVID-19: ПРОВЕРКА ГИПОТЕЗЫ

Резюме
Пандемия коронавирусного заболевания 2019 года (COVID-19) поглотила медицинское сообщество в клинике, лаборатории и библиотеке. Поскольку мир имеет дело с этим быстро мутирующими вирусом, важно поиски лучшего кандидата на вакцину, необходимо продолжить усилия по перепрофилированию существующих молекул для спасения жизней. Большой интерес вызвали последние дефицита витамина D и приема добавок этого витамина для исходов у пациентов с COVID-19. Мы предполагаем, что добавка витамина D может обеспечить защиту от тяжелого острого респираторного синдрома, вызванного коронавирусом 2 (SARS-CoV-2), и тяжелого COVID-19. Различные исследования на животных и людях, а также интервенционные исследования показали защитную роль витамина D при COVID-19. Чтобы определить точный вклад этой добавки в предотвращение инфекции и изменение течения COVID-19, необходимы более тщательно продуманные исследования, в которых витамин D вводится с профилактической целью и вводится тем, кто уже инфицирован.

Ключевые слова: коронавирусная болезнь 2019, тяжелый острый респираторный синдром, коронавирус 2, пандемия, холекальциферол, кальцитриол, клинические испытания

Для цитирования: Гоял М., Гоял Н. Роль витамина D в профилактике распространения инфекции и тяжелого течения заболевания при COVID-19: проверка гипотезы. Центральноазиатский журнал медицинских гипотез и этики. 2021:2(3):146-152. https://doi.org/10.47316/cajmhe.2021.2.3.03